BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 316 participants.

Also called NCT06059638

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 316 participants (planned count) (from the registry)
Sponsor
  • Medtronic Registry lists this organization as a collaborator
Registry
  • NCT NCT06059638
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Australia, Belgium, China, Czechia, France, Germany, Hungary, Italy, Netherlands, New Zealand, Poland, Spain, Switzerland, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06059638. Randomized; triple masking; primary purpose treatment. Start 2023-12-27 (actual); primary completion 2026-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
Acronym
BACKBEAT
Condition
Hypertension
Condition
Hypertension, Systolic
Condition
Hypertension, Essential
Intervention (Device)
Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated
Intervention (Device)
Medtronic Astra/Azure DR MRI IPG with AVIM therapy Deactivated
Lead sponsor
Orchestra BioMed, Inc (class: industry)
Collaborator
Medtronic (class: industry)

Record details

Record id
cardio:ct-nct06059638
Content hash
51c9f128a918b70d1eca04e1579d3b742df675acfcb0c71cdd40d768e05b1354